1. Home
  2. CTSO vs IXHL Comparison

CTSO vs IXHL Comparison

Compare CTSO & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

N/A

Current Price

$0.73

Market Cap

45.7M

Sector

Health Care

ML Signal

N/A

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

N/A

Current Price

$5.95

Market Cap

97.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CTSO
IXHL
Founded
1997
2001
Country
United States
Australia
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.7M
97.6M
IPO Year
2008
2024

Fundamental Metrics

Financial Performance
Metric
CTSO
IXHL
Price
$0.73
$5.95
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$5.38
N/A
AVG Volume (30 Days)
67.1K
4.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$22,503,908.00
$12,000.00
Revenue This Year
$7.29
N/A
Revenue Next Year
$8.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.53
N/A
52 Week Low
$0.60
$0.11
52 Week High
$1.39
$5.45

Technical Indicators

Market Signals
Indicator
CTSO
IXHL
Relative Strength Index (RSI) 54.78 90.18
Support Level $0.62 $0.31
Resistance Level $0.84 N/A
Average True Range (ATR) 0.04 0.37
MACD 0.01 0.40
Stochastic Oscillator 59.46 91.05

Price Performance

Historical Comparison
CTSO
IXHL

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: